Overview

An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients

Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability, pharmacokinetics, and efficacy of the Lu AE04621 and metabolite after ascending oral doses of Lu AE04621 in patients with Parkinson's Disease.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lundbeck A/S